Skip to main content

Center for Advanced Regenerative Engineering

Unlocking our Body's Potential to Heal

Learn More About CARE

The Center for Advanced Regenerative Engineering is Hiring Post-Doctoral Fellows

CARE has open positions for Postdoctoral Fellows in the following areas:

1) Regenerative biomaterials and devices for improving the outcome of cardiovascular medical procedures

2) Musculoskeletal, bladder, and cardiovascular regenerative engineering research

Read more about the positions and qualifications here.

Biomaterial pioneered in CARE available for use in musculoskeletal surgeries

September 24, 2021

Citregen reabsorption. Photo credit: Acuitive Technologies
Citregen reabsorption. Photo credit: Acuitive Technologies

 

Biomaterial developed in CARE labs to be widely available through a device by Stryker Corporation

The novel biomaterial Citregen™, developed in the Center for Advanced Regenerative Engineering, is being adopted into a new orthopaedic device being distributed by Stryker.  Stryker is one of the world’s leading medical technology companies, and their Trauma & Extremities division has launched its Citrelock™ Tendon Fixation Device System.  Citregen’s unique chemical and mechanical properties make this system an innovative offering in a number of ways.  For example, it provides a controlled and homogeneous resorption process that prevents bulk degradation and chronic inflammation, and maintains structural integrity during the healing phase, while the implant is replaced by host tissue.

Citrelock will be featured during one of Stryker’s industry sessions at AOFAS on Sept. 24. The company is also hosting a new product reception highlighting the benefits of Citrelock along with other recent additions to its Foot & Ankle portfolio. 

Read Stryker’s press release, find more information about Stryker’s product release here.

The development and commercialization of a novel biomaterial is a rare accomplishment.  Read an article in Northwester Now by Lila Reynolds that features the development of CITREGEN™ in Dr. Ameer's labs.

 

 

Medical devices created in CARE receive FDA clearance

March 4, 2021

Above: CITRESPLINE/CITRELOCK™ System

Above: CITRESPLINE/CITRELOCK™ System

Acuitive Technologies, Inc.  announced on March 4, 2021, U.S. Food and Drug Administration (FDA) approval of a third device designed using the core material technology CITREGEN, pioneered by Dr. Guillermo Ameer and his lab.

The CITRESPLINE/CITRELOCK™ system is intended to firmly engage tendons and ligaments within a bone tunnel while preserving the integrity of the soft tissue during insertion of the device. These products are intended to be used during orthopedic surgeries for fixation of ligament or tendon tissue repairs of the knee, shoulder, elbow, wrist, hand, ankle, and foot.  Acuitivie Technologies, Inc. intends to commercialize the CITRESPLINE and CITRELOCK System with an orthopedic distribution partner to compete in the Sports Medicine market. 

Read the full press release by Acuitive Technologies, Inc. here.

Learn more about CITREGEN™ technology.

 

February 15, 2021

CITREFIX™ Knotless Suture Anchor System

Above: CITREFIX™ Knotless Suture Anchor System

On February 11, 2021, Acuitive Technologies announced a second product that uses CITREGEN™ material technology has also received FDA clearance.  The CITREFIX™ Knotless Suture Anchor System is intended to assist the attachment of tissue to bone during orthopedic surgeries such as fixation of ligaments or tendon graft tissue repairs of the shoulder, elbow, wrist, hand, knee, ankle, and foot extremities.  Read more about the product and announcement here.

 

CITRELOCK tendon fixation devices. Credit: Acuitive Technologies

Above: CITRELOCK tendon fixation devices. Credit: Acuitive Technologies

The Center for Advanced Regenerative Engineering, led by its director  Guillermo Ameer, has pioneered an innovative orthopedic medical device fabricated from a novel biomaterial, and has received clearance from the U.S. Food and Drug Administration (FDA) for use in surgeries to attach soft tissue grafts to bone.
The biomaterial is the first thermoset biodegradable synthetic polymer ever approved for use in an implantable medical device.  Ameer’s biomaterial, called CITREGEN™, helps grafted tissues heal by recreating their intrinsic biochemical and structural support network.  CITREGEN™ is the core material technology in the CITRELOCK™ Interference Screw System, which will be produced and marketed by Acuitive Technologies, Inc. The system is intended for soft tissue attachment or fixing ligaments and tendon graft tissue in joint surgeries.  “CITREGEN is an unprecedented and innovative bioresorbable biomaterial technology developed to support the body’s normal healing process and promote tissue regeneration,” Ameer said. “When used to fabricate devices for reconstruction of tissues, such as ligaments, blood vessels, bladder and bone, results have been impressive and beyond our expectations.”

Read the full story about the device as covered by Northwestern News.

 The CITRELOCK Interference Screw System will become available through Acuitive’s orthopaedic distribution partner in early 2021.  Read more about Acuitive's FDA Clearance in this release.

 

What is CARE

Housed within the McCormick School of Engineering and Applied Science, the Center for Advanced Regenerative Engineering (CARE) is a targeted initiative led by Prof. Guillermo Ameer that integrates and supports research, technology development, and clinical expertise to improve the outcome of tissue and organ repair and regeneration for adult and pediatric patients. CARE is a partnership that includes Northwestern University's Feinberg School of Medicine, the University of Chicago's Pritzker School of Medicine, the Shirley Ryan AbilityLab, the Ann and Robert H. Lurie Children’s Hospital of Chicago, the International Institute for Nanotechnology, and various companies interested in the implementation of regenerative medicine.

Back to top